Delivery Order SPE2DB20D3103-SPE2DB25FP7Z8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a contract ceiling value of $29,588.62. This firm fixed-price delivery order, which is expected to conclude by August 15, 2025, represents a competitively awarded, non-set-aside contract with performance directed to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award demonstrates the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $10,940.38. This firm fixed-price delivery order, which is not set-aside and represents the culmination of competitive procurement, is scheduled for completion by August 7, 2025. The award supports the federal medical supply chain, with performance occurring at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $35,436.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a single line item fulfilling pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $17,620.78 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $13,807.38. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award to this qualified pharmaceutical vendor. The order is scheduled for completion by September 9, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $7,386.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $19,860.97 delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on June 26, 2025, with completion expected by June 27, 2025. This firm fixed-price contract represents a non-competitive set-aside and reflects AmerisourceBergen's critical role as a pharmaceutical distributor supporting federal medical procurement needs. The order is being performed at the contractor's corporate office location in...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $8,268.87. This competitively awarded, firm fixed-price delivery order is non-set-aside and reflects the contractor's ongoing role as a critical pharmaceutical vendor supporting federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $27,320.78. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for supply of Otezla 30 mg tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $48,488.62 with an ultimate completion date of July 30, 2025, represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP7Z8Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Otezla 30 mg tablets (60-count units) at a firm fixed price with a ceiling value of $40,194.81 and an ultimate completion date of August 11, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's ongoing support to federal medical procurement under its larger contract vehicle. The delivery is scheduled to take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal healthcare systems, AmerisourceBergen leverages this comprehensive IDC to supply a broad range of pharmaceutical products, medical devices, and specialized healthcare commodities to support military health programs globally, including serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. The contract demonstrates the company's capability to fulfill competitive federal procurement requirements across diverse pharmaceutical therapeutic domains on firm fixed-price terms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.2k | 8/8/25 |